• Govconnect

Mental health 2019 - Partner Profile - Magventure

Who are Magventure?

MagVenture's mission is to be the most dynamic and innovative supplier of transcranial magnetic stimulation solutions. Many "first mover" features and improvements have been developed over the years in response to ideas and requests from our customers.

Grounded in research, committed to treatment, and focused on results, we will continue to invest in developing TMS solutions of superior quality for both research and clinical use. Our ultimate goal is to help facilitate new treatment options for those who need it.

How has Magventure improved people’s mental health in the UK?

MagVenture are one of the largest TMS suppliers in the UK supporting practitioners to make this non-invasive treatment accessible to those affected by depression and other mental health conditions.

What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?

MagVenture have been selling transcranial magnetic stimulation devices and TMS coils since 1992 and we are now represented in over 50 countries.

In 2011, we were the first TMS provider to receive CE approval for its depression treatment system known as MagVita TMS Therapy, now named MagVenture TMS Therapy. In 2015 we then received FDA clearance for the treatment of major depressive disorder.

In 2018 MagVenture also received FDA clearance for a 3 minute TBS depression treatment. This TBS (Theta burst stimulation) protocol is based on the world’s largest Randomized Control Trial with TMS to date. The article was published in the Lancet [Blumberger et al, 2018, The Lancet].

How many organisations/clients currently utilise the service/solution across the UK?


What do you feel are the key points delegates need to digest when considering a partnership with Magventure?

Providing safe treatment solutions that are highly effective, and comfortable for the patient, as well as reliable and easy to use for the healthcare practitioners is a key priority for us.

TMS for the treatment of major depressive disorder is already established as an effective treatment for patients not responding to conventional treatment such as antidepressants.

While maintaining a constant focus on developing the best TMS equipment for TMS treatment, we are very pleased to see an increasing number of government and healthcare authorities worldwide implementing TMS therapy in their care systems.

We strive to see results within both research and clinical use. Evidence-based research in the form of clinical trials is one of the key drivers which will help move the field further and will, hopefully, lead to new treatment protocols.

If you would like to learn more about Magventure please visit https://www.magventure.com/

7,954 views0 comments

Copyright © 2019 Govconnect. All Rights Reserved